unlisted autologous T cell therapy with anti-CD19-TCR-4-1BB construct
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for unlisted autologous T cell therapy with anti-CD19-TCR-4-1BB construct, covering 2019-05-24 to 2019-05-24. Get the full timeline:
Most recent: Clinical Trial Update: Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia [Phase 2]